

Iconovo's ICOone® inhaler platform receives new patent approval in the US

Iconovo AB (publ), that develops inhalation products for a global market, today announced that the United States Patent and Trademark Office (USPTO) intends to approve an additional patent for ICOone® – an innovative inhaler platform that enables convenient and cost-effective administration of vaccines and biologics. Iconovo is already pursuing several development projects based on ICOone®, including one with financial support from the Bill & Melinda Gates Foundation.

ICOone® is Iconovo's inhaler platform for convenient and cost-effective administration of vaccines and biologics. Since ICOone® can be loaded with the active ingredient in the form of a dry powder, expensive and complicated cold storage is not required. In addition, it avoids the handling of disposable syringes and used needles that can spread blood-borne infections. Today's announcement from the USPTO means that ICOone® will be protected by two patents in the US market. The inhaler also has patent protection in the rest of Europe (EPO), India, China, and Japan.

"Today's positive announcement from the US Patent and Trademark Office underlines the innovative nature of ICOone, our unique single-use inhaler that offers ease of use and ultra-low manufacturing cost. We look forward to continuing to contribute to the development of both new originator drugs and vaccines through established and new revenue-generating customer partnerships," said Dr. Orest Lastow, Chief Technology Officer of Iconovo.

Iconovo's latest collaborative project based on ICOone® was established in July 2022 with the Bill & Melinda Gates Foundation and aims to develop new inhaled therapies for the next viral pandemic. Previously, a collaboration with Monash University, supported by Janssen Pharmaceuticals, on a preventive treatment for postpartum hemorrhage based on the drug substance oxytocin, is underway. Iconovo is also collaborating with the Swedish pharmaceutical companies Arcede and ISR on the development of a novel drug treatment for COPD and asthma and an inhalable covid-19 vaccine, respectively.

About ICOone®

ICOone® is a unique and patented dry powder inhaler designed for singleuse. Its clever design provides an ultra-low manufacturing cost combined with ease and discretion of use. The simple design also allows patients and healthcare professionals to learn how to use the inhaler with minimal training. ICOone® can deliver large inhalation doses that are well protected from moisture, which is important for many biomolecules.

<https://iconovo.se/products/icoone/>

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2024. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Erik Penser Bank AB.

Attachments

[Iconovo's ICOone® inhaler platform receives new patent approval in the US](#)